Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Hereditary Autoinflammatory Disease

Interventions

DRUG

Lanadelumab

300mg Lanadelumab s.c. administration every 2 weeks

Trial Locations (1)

Charite University, Berlin, Germany, Berlin

All Listed Sponsors

collaborator

Shire International GmbH

UNKNOWN

lead

Charite University, Berlin, Germany

OTHER